Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDTX Black Diamond Therapeutics	$2.79 +0.7%	$2.65	$1.20 ▼ $6.75	$157.71M	2.87	919,991 shs	1.08 million shs
FATE Fate Therapeutics	$1.07 -5.3%	$1.17	$0.66 ▼ $4.20	$130.32M	2.24	1.53 million shs	1.68 million shs
KYTX Kyverna Therapeutics	$3.54 +2.0%	$3.44	$1.78 ▼ $8.78	$150.06M	3.05	232,736 shs	256,816 shs
XLO Xilio Therapeutics	$0.70 -1.7%	$0.69	$0.62 ▼ $1.70	$37.01M	-0.15	421,632 shs	415,714 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDTX Black Diamond Therapeutics	+0.72%	+22.37%	-5.42%	+43.08%	-44.20%
FATE Fate Therapeutics	-5.31%	+9.17%	-5.31%	0.00%	-67.28%
KYTX Kyverna Therapeutics	+2.02%	+6.95%	-7.33%	+52.59%	-47.56%
XLO Xilio Therapeutics	-1.68%	+7.22%	-1.46%	-18.23%	-14.80%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BDTX Black Diamond Therapeutics	3.2526 of 5 stars	3.5	1.0	0.0	3.8	1.7	1.9
FATE Fate Therapeutics	4.0602 of 5 stars	3.1	2.0	4.7	2.3	2.5	0.6
KYTX Kyverna Therapeutics	2.915 of 5 stars	3.6	2.0	0.0	3.8	1.7	0.6
XLO Xilio Therapeutics	2.8356 of 5 stars	3.7	2.0	0.0	2.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDTX Black Diamond Therapeutics	3.00	Buy	$12.40	344.44% Upside
FATE Fate Therapeutics	2.13	Hold	$3.58	234.89% Upside
KYTX Kyverna Therapeutics	3.17	Buy	$15.60	340.68% Upside
XLO Xilio Therapeutics	3.33	Buy	$3.00	326.92% Upside

Current Analyst Ratings Breakdown

Latest XLO, FATE, KYTX, and BDTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	FATE Fate Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$4.00 ➝ $2.50
8/11/2025	BDTX Black Diamond Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
8/6/2025	XLO Xilio Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/6/2025	XLO Xilio Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$2.00
7/1/2025	BDTX Black Diamond Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform	$11.00
6/12/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/27/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $5.00
5/14/2025	FATE Fate Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$10.00 ➝ $2.00
5/14/2025	FATE Fate Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $4.00
5/14/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	$2.33 per share	N/A
FATE Fate Therapeutics	$13.63M	9.05	N/A	N/A	$2.27 per share	0.47
KYTX Kyverna Therapeutics	$7.03M	21.78	N/A	N/A	$4.26 per share	0.83
XLO Xilio Therapeutics	$6.34M	5.74	N/A	N/A	$0.40 per share	1.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDTX Black Diamond Therapeutics	-$69.68M	$0.23	12.13	N/A	N/A	N/A	12.70%	9.58%	N/A
FATE Fate Therapeutics	-$186.26M	-$1.49	N/A	N/A	N/A	-2,025.05%	-50.95%	-36.76%	N/A
KYTX Kyverna Therapeutics	-$127.48M	-$3.68	N/A	N/A	N/A	N/A	-64.98%	-56.17%	N/A
XLO Xilio Therapeutics	-$58.24M	-$0.84	N/A	N/A	N/A	-585.54%	-262.69%	-64.01%	8/14/2025 (Estimated)

Latest XLO, FATE, KYTX, and BDTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	XLO Xilio Therapeutics	-$0.10	-$0.16	-$0.06	-$0.16	N/A	N/A
8/12/2025	Q2 2025	FATE Fate Therapeutics	-$0.35	-$0.29	+$0.06	-$0.29	$1.16 million	$1.91 million
8/12/2025	Q2 2025	KYTX Kyverna Therapeutics	-$1.00	-$0.97	+$0.03	-$0.97	N/A	N/A
8/7/2025	Q2 2025	BDTX Black Diamond Therapeutics	-$0.25	-$0.19	+$0.06	-$0.19	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
XLO Xilio Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDTX Black Diamond Therapeutics	N/A	8.73	8.73
FATE Fate Therapeutics	N/A	8.04	8.81
KYTX Kyverna Therapeutics	N/A	5.39	7.44
XLO Xilio Therapeutics	N/A	1.96	1.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDTX Black Diamond Therapeutics	95.47%
FATE Fate Therapeutics	97.54%
KYTX Kyverna Therapeutics	18.08%
XLO Xilio Therapeutics	54.29%

Insider Ownership

Company	Insider Ownership
BDTX Black Diamond Therapeutics	5.97%
FATE Fate Therapeutics	5.51%
KYTX Kyverna Therapeutics	22.00%
XLO Xilio Therapeutics	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDTX Black Diamond Therapeutics	90	56.94 million	53.54 million	Optionable
FATE Fate Therapeutics	550	115.33 million	108.29 million	Optionable
KYTX Kyverna Therapeutics	96	43.25 million	33.71 million	Optionable
XLO Xilio Therapeutics	70	51.78 million	49.09 million	Not Optionable

XLO, FATE, KYTX, and BDTX Headlines

Recent News About These Companies

Xilio Therapeutics reports Q2 EPS (16c) vs (24c) last year

3 hours ago | msn.com

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

3 hours ago | taiwannews.com.twT

Xilio Revenue Jumps 246 Percent in Q2

3 hours ago | aol.comA

Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates

August 14 at 9:36 AM | zacks.com

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

August 14 at 7:30 AM | globenewswire.com

Xilio Therapeutics (XLO) Expected to Announce Quarterly Earnings on Thursday

August 12 at 3:27 AM | americanbankingnews.com

Brokers Set Expectations for XLO Q2 Earnings

August 10, 2025 | americanbankingnews.com

Leerink Partners Begins Coverage on Xilio Therapeutics (NASDAQ:XLO)

August 8, 2025 | americanbankingnews.com

Leerink Partners Initiates Coverage of Xilio Therapeutics (XLO) with Outperform Recommendation

August 7, 2025 | msn.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 1, 2025 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - Morningstar

July 3, 2025 | morningstar.comM

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 2, 2025 | globenewswire.com

James Samuel Shannon Acquires 25,000 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) Stock

June 19, 2025 | insidertrades.com

Xilio Therapeutics expands board, elects new director

June 12, 2025 | investing.com

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to Board of Directors

June 10, 2025 | quiverquant.comQ

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

June 10, 2025 | globenewswire.com

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

June 5, 2025 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 3, 2025 | globenewswire.com

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering

June 2, 2025 | globenewswire.com

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite ...

June 2, 2025 | stockhouse.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XLO, FATE, KYTX, and BDTX Company Descriptions

Black Diamond Therapeutics NASDAQ:BDTX

$2.79 +0.02 (+0.72%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$2.82 +0.02 (+0.90%)

As of 04:28 AM Eastern

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Fate Therapeutics NASDAQ:FATE

$1.07 -0.06 (-5.31%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.17 +0.10 (+9.25%)

As of 04:06 AM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Kyverna Therapeutics NASDAQ:KYTX

$3.54 +0.07 (+2.02%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$3.54 0.00 (0.00%)

As of 08/14/2025 04:10 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Xilio Therapeutics NASDAQ:XLO

$0.70 -0.01 (-1.68%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$0.71 +0.01 (+1.18%)

As of 08/14/2025 07:38 PM Eastern

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time